The AURORA initiative for metastatic breast cancer

D. Zardavas, M. Maetens, A. Irrthum, T. Goulioti, K. Engelen, D. Fumagalli, R. Salgado, P. Aftimos, K. S. Saini, C. Sotiriou, P. Campbell, P. Dinh, G. Von Minckwitz, R. D. Gelber, M. Dowsett, A. Di Leo, D. Cameron, J. Baselga, M. Gnant, A. Goldhirsch & 2 others L. Norton, M. Piccart

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused on the molecular analysis of the primary tumour to dissect the genotypes of the disease. However, accumulating evidence supports a molecular evolution of breast cancer during its life cycle, with metastatic lesions acquiring new molecular aberrations. Recognising this critical gap of knowledge, the Breast International Group is launching AURORA, a large, multinational, collaborative metastatic breast cancer molecular screening programme. Approximately 1300 patients with metastatic breast cancer who have received no more than one line of systemic treatment for advanced disease will, after giving informed consent, donate archived primary tumour tissue, as well as will donate tissue collected prospectively from the biopsy of metastatic lesions and blood. Both tumour tissue types, together with a blood sample, will then be subjected to next generation sequencing for a panel of cancer-related genes. The patients will be treated at the discretion of their treating physicians per standard local practice, and they will be followed for clinical outcome for 10 years. Alternatively, depending on the molecular profiles found, patients will be directed to innovative clinical trials assessing molecularly targeted agents. Samples of outlier patients considered as 'exceptional responders' or as 'rapid progressors' based on the clinical follow-up will be subjected to deeper molecular characterisation in order to identify new prognostic and predictive biomarkers. AURORA, through its innovative design, will shed light onto some of the unknown areas of metastatic breast cancer, helping to improve the clinical outcome of breast cancer patients.

Original languageEnglish
Pages (from-to)1881-1887
Number of pages7
JournalBritish Journal of Cancer
Volume111
Issue number10
DOIs
Publication statusPublished - Nov 11 2014

Fingerprint

Breast Neoplasms
Neoplasms
Western World
Molecular Evolution
Neoplasm Genes
Life Cycle Stages
Informed Consent
Early Detection of Cancer
Breast
Biomarkers
Genotype
Clinical Trials
Physicians
Biopsy
Mortality
Research
Therapeutics

Keywords

  • breast cancer
  • metastatic
  • molecular profiling
  • next generation sequencing
  • targeted clinical trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zardavas, D., Maetens, M., Irrthum, A., Goulioti, T., Engelen, K., Fumagalli, D., ... Piccart, M. (2014). The AURORA initiative for metastatic breast cancer. British Journal of Cancer, 111(10), 1881-1887. https://doi.org/10.1038/bjc.2014.341

The AURORA initiative for metastatic breast cancer. / Zardavas, D.; Maetens, M.; Irrthum, A.; Goulioti, T.; Engelen, K.; Fumagalli, D.; Salgado, R.; Aftimos, P.; Saini, K. S.; Sotiriou, C.; Campbell, P.; Dinh, P.; Von Minckwitz, G.; Gelber, R. D.; Dowsett, M.; Di Leo, A.; Cameron, D.; Baselga, J.; Gnant, M.; Goldhirsch, A.; Norton, L.; Piccart, M.

In: British Journal of Cancer, Vol. 111, No. 10, 11.11.2014, p. 1881-1887.

Research output: Contribution to journalArticle

Zardavas, D, Maetens, M, Irrthum, A, Goulioti, T, Engelen, K, Fumagalli, D, Salgado, R, Aftimos, P, Saini, KS, Sotiriou, C, Campbell, P, Dinh, P, Von Minckwitz, G, Gelber, RD, Dowsett, M, Di Leo, A, Cameron, D, Baselga, J, Gnant, M, Goldhirsch, A, Norton, L & Piccart, M 2014, 'The AURORA initiative for metastatic breast cancer', British Journal of Cancer, vol. 111, no. 10, pp. 1881-1887. https://doi.org/10.1038/bjc.2014.341
Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D et al. The AURORA initiative for metastatic breast cancer. British Journal of Cancer. 2014 Nov 11;111(10):1881-1887. https://doi.org/10.1038/bjc.2014.341
Zardavas, D. ; Maetens, M. ; Irrthum, A. ; Goulioti, T. ; Engelen, K. ; Fumagalli, D. ; Salgado, R. ; Aftimos, P. ; Saini, K. S. ; Sotiriou, C. ; Campbell, P. ; Dinh, P. ; Von Minckwitz, G. ; Gelber, R. D. ; Dowsett, M. ; Di Leo, A. ; Cameron, D. ; Baselga, J. ; Gnant, M. ; Goldhirsch, A. ; Norton, L. ; Piccart, M. / The AURORA initiative for metastatic breast cancer. In: British Journal of Cancer. 2014 ; Vol. 111, No. 10. pp. 1881-1887.
@article{5a09f320c8b440a79715fc83969b1bf4,
title = "The AURORA initiative for metastatic breast cancer",
abstract = "Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused on the molecular analysis of the primary tumour to dissect the genotypes of the disease. However, accumulating evidence supports a molecular evolution of breast cancer during its life cycle, with metastatic lesions acquiring new molecular aberrations. Recognising this critical gap of knowledge, the Breast International Group is launching AURORA, a large, multinational, collaborative metastatic breast cancer molecular screening programme. Approximately 1300 patients with metastatic breast cancer who have received no more than one line of systemic treatment for advanced disease will, after giving informed consent, donate archived primary tumour tissue, as well as will donate tissue collected prospectively from the biopsy of metastatic lesions and blood. Both tumour tissue types, together with a blood sample, will then be subjected to next generation sequencing for a panel of cancer-related genes. The patients will be treated at the discretion of their treating physicians per standard local practice, and they will be followed for clinical outcome for 10 years. Alternatively, depending on the molecular profiles found, patients will be directed to innovative clinical trials assessing molecularly targeted agents. Samples of outlier patients considered as 'exceptional responders' or as 'rapid progressors' based on the clinical follow-up will be subjected to deeper molecular characterisation in order to identify new prognostic and predictive biomarkers. AURORA, through its innovative design, will shed light onto some of the unknown areas of metastatic breast cancer, helping to improve the clinical outcome of breast cancer patients.",
keywords = "breast cancer, metastatic, molecular profiling, next generation sequencing, targeted clinical trials",
author = "D. Zardavas and M. Maetens and A. Irrthum and T. Goulioti and K. Engelen and D. Fumagalli and R. Salgado and P. Aftimos and Saini, {K. S.} and C. Sotiriou and P. Campbell and P. Dinh and {Von Minckwitz}, G. and Gelber, {R. D.} and M. Dowsett and {Di Leo}, A. and D. Cameron and J. Baselga and M. Gnant and A. Goldhirsch and L. Norton and M. Piccart",
year = "2014",
month = "11",
day = "11",
doi = "10.1038/bjc.2014.341",
language = "English",
volume = "111",
pages = "1881--1887",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - The AURORA initiative for metastatic breast cancer

AU - Zardavas, D.

AU - Maetens, M.

AU - Irrthum, A.

AU - Goulioti, T.

AU - Engelen, K.

AU - Fumagalli, D.

AU - Salgado, R.

AU - Aftimos, P.

AU - Saini, K. S.

AU - Sotiriou, C.

AU - Campbell, P.

AU - Dinh, P.

AU - Von Minckwitz, G.

AU - Gelber, R. D.

AU - Dowsett, M.

AU - Di Leo, A.

AU - Cameron, D.

AU - Baselga, J.

AU - Gnant, M.

AU - Goldhirsch, A.

AU - Norton, L.

AU - Piccart, M.

PY - 2014/11/11

Y1 - 2014/11/11

N2 - Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused on the molecular analysis of the primary tumour to dissect the genotypes of the disease. However, accumulating evidence supports a molecular evolution of breast cancer during its life cycle, with metastatic lesions acquiring new molecular aberrations. Recognising this critical gap of knowledge, the Breast International Group is launching AURORA, a large, multinational, collaborative metastatic breast cancer molecular screening programme. Approximately 1300 patients with metastatic breast cancer who have received no more than one line of systemic treatment for advanced disease will, after giving informed consent, donate archived primary tumour tissue, as well as will donate tissue collected prospectively from the biopsy of metastatic lesions and blood. Both tumour tissue types, together with a blood sample, will then be subjected to next generation sequencing for a panel of cancer-related genes. The patients will be treated at the discretion of their treating physicians per standard local practice, and they will be followed for clinical outcome for 10 years. Alternatively, depending on the molecular profiles found, patients will be directed to innovative clinical trials assessing molecularly targeted agents. Samples of outlier patients considered as 'exceptional responders' or as 'rapid progressors' based on the clinical follow-up will be subjected to deeper molecular characterisation in order to identify new prognostic and predictive biomarkers. AURORA, through its innovative design, will shed light onto some of the unknown areas of metastatic breast cancer, helping to improve the clinical outcome of breast cancer patients.

AB - Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused on the molecular analysis of the primary tumour to dissect the genotypes of the disease. However, accumulating evidence supports a molecular evolution of breast cancer during its life cycle, with metastatic lesions acquiring new molecular aberrations. Recognising this critical gap of knowledge, the Breast International Group is launching AURORA, a large, multinational, collaborative metastatic breast cancer molecular screening programme. Approximately 1300 patients with metastatic breast cancer who have received no more than one line of systemic treatment for advanced disease will, after giving informed consent, donate archived primary tumour tissue, as well as will donate tissue collected prospectively from the biopsy of metastatic lesions and blood. Both tumour tissue types, together with a blood sample, will then be subjected to next generation sequencing for a panel of cancer-related genes. The patients will be treated at the discretion of their treating physicians per standard local practice, and they will be followed for clinical outcome for 10 years. Alternatively, depending on the molecular profiles found, patients will be directed to innovative clinical trials assessing molecularly targeted agents. Samples of outlier patients considered as 'exceptional responders' or as 'rapid progressors' based on the clinical follow-up will be subjected to deeper molecular characterisation in order to identify new prognostic and predictive biomarkers. AURORA, through its innovative design, will shed light onto some of the unknown areas of metastatic breast cancer, helping to improve the clinical outcome of breast cancer patients.

KW - breast cancer

KW - metastatic

KW - molecular profiling

KW - next generation sequencing

KW - targeted clinical trials

UR - http://www.scopus.com/inward/record.url?scp=84927177712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927177712&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.341

DO - 10.1038/bjc.2014.341

M3 - Article

VL - 111

SP - 1881

EP - 1887

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -